Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 57Myeloid 27Lymphoid 8Classical hematology 4Head & Neck 3Gynecologic 3Dermatologic 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1Breast 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 2Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Cytopenia 1Congenital Bone Marrow Failure Syndromes 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 24fludarabine phosphate 18Whole-Body Irradiation 17fludarabine 16Mycophenolic Acid 16Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Busulfan 12Melphalan 11apixaban 10Biopsy 7Rivaroxaban 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Filgrastim 5Cyclosporine 5Azacitidine 5thymoglobulin 4X-Rays 4Sirolimus 4Rituximab 4Injections 4Enoxaparin 4Decitabine 4Bone Marrow Transplantation 4Aspirin 4Antilymphocyte Serum 4venetoclax 3pegylated granulocyte colony-stimulating factor 3hetrombopag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Decitabine × Classical hematology × 1 year × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

NCT05796570 2026-03-19

MORE

Dana-Farber Cancer Institute

Phase 2 Recruiting
37 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Bone Marrow Failure Syndromes, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
8 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡